Calidi Biotherapeutics
CLDI
21 hedge funds and large institutions have $354K invested in Calidi Biotherapeutics in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 18 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
3.24% more ownership
Funds ownership: 0% → 3.24% (+3.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
38% less funds holding
Funds holding: 34 → 21 (-13)
46% less capital invested
Capital invested by funds: $656K → $354K (-$302K)
67% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$319K |
| 2 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
+$88.5K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$79.4K |
| 4 |
RCI
RS Crum Inc
Newport Beach,
California
|
+$64.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$43.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$182K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$97.2K |
| 3 |
CI
CPR Investments
Rochester,
Michigan
|
-$23.2K |
| 4 |
RWI
Red Wave Investments
Dillsburg,
Pennsylvania
|
-$18.6K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$16.4K |
CLDI Hedge Fund Activity: Q3 2025 in Review
21 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q3 2025, worth a combined $354K — down 46% from $656K a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CLDI and 6 opened new positions — a net loss of 12 holders — while 2 trimmed existing stakes and 6 added.
The largest buyer was HighTower Advisors, adding an estimated $319K. The largest seller was Armistice Capital, exiting entirely with an estimated $182K sold.
- 21 institutional investors held Calidi Biotherapeutics (CLDI) as of Q3 2025, down from 34 in Q2 2025.
- Funds reported $354K of Calidi Biotherapeutics stock for Q3 2025, down 46% quarter-over-quarter.
- 6 funds opened new Calidi Biotherapeutics positions in Q3 2025 and 18 closed out, a net change of -12 holders.
- The largest Calidi Biotherapeutics buyer in Q3 2025 was HighTower Advisors, an estimated $319K added.
- The largest Calidi Biotherapeutics seller in Q3 2025 was Armistice Capital, an estimated $182K sold.
Based on aggregated 13F filings for Q3 2025.